



Universiteit
Leiden
The Netherlands

The effect of statin therapy on vessel wall properties in type 2 diabetes without manifest cardiovascular disease

Beishuizen, E.D.

Citation

Beishuizen, E. D. (2008, December 4). *The effect of statin therapy on vessel wall properties in type 2 diabetes without manifest cardiovascular disease*. Retrieved from <https://hdl.handle.net/1887/13309>

Version: Corrected Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/13309>

Note: To cite this publication please use the final published version (if applicable).

**The effect of statin therapy on vessel wall
properties in type 2 diabetes without
manifest cardiovascular disease**

Edith Dorothé Beishuizen

ISBN 978-90-8559-458-1

Omslag en ontwerp: José Beishuizen-Tabak

Omslag, layout en druk: Optima Grafische Communicatie, Rotterdam

De hoofdsponsors voor de studies beschreven in dit proefschrift zijn:

Bayer BV, Mijdrecht, Nederland

Merck Sharp & Dohme B.V., Haarlem, Nederland

Pfizer bv, Capelle a/d IJssel, Nederland

De druk van dit proefschrift werd gedeeltelijk gefinancierd door:

AstraZeneca BV; Boehringer Ingelheim bv; Eli Lilly Nederland BV; Merck Sharp & Dohme B.V.; Novartis Pharma B.V.; Novo Nordisk B.V.; Pfizer bv; Schering-Plough BV; Servier Nederland Farma B.V.

The effect of statin therapy on vessel wall properties in type 2 diabetes without manifest cardiovascular disease

PROEFSCHRIFT

ter verkrijging van
de graad van Doctor aan de Universiteit Leiden,
op gezag van de Rector Magnificus prof.mr.P.F. van der Heijden,
volgens besluit van het College voor Promoties
te verdedigen op donderdag 4 december 2008
klokke 15.00 uur

door

Edith Dorothé Beishuizen

geboren te Amsterdam
in 1966

Promotiecommissie

Promotores: Prof.dr.A.E. Meinders
Prof.dr.J.W. Jukema

Co-promotores: Dr.M.V. Huisman
Dr.J.T. Tamsma

Referent: Prof.dr.J.B.L. Hoekstra

Overige leden: Prof.dr.J.A. Romijn
Prof.dr.A.J. Rabelink
Dr.J.C.M. van der Vijver , HAGA Ziekenhuis, locatie Leyenburg, Den Haag

Voor mijn ouders

Contents

List of abbreviations		9
Chapter 1	Introduction	11
Chapter 2	Non-invasive cardiac imaging techniques and vascular tools for the assessment of cardiovascular disease in type 2 Diabetes Mellitus Diabetologia 2008; 51:1581-1593	19
Chapter 3	Two year statin therapy does not alter the progression of Intima-Media Thickness in patients with type 2 diabetes mellitus without manifest cardiovascular disease Diabetes Care 2004; 27: 2887-2892	41
Chapter 4	The effect of statin therapy on endothelial function in type 2 diabetes mellitus without manifest cardiovascular disease Diabetes Care 2005; 28: 1668-1674	55
Chapter 5	Differential effects of statin therapy on CRP in patients with type 2 diabetes with and without the metabolic syndrome Submitted	69
Chapter 6	The impact of metabolic syndrome and CRP on vascular phenotype in type 2 diabetes mellitus European Journal of Internal Medicine 2008; 19:115-121	81
Chapter 7	Vascular phenotype and subclinical inflammation in diabetic Asian Indians without overt cardiovascular disease Diabetes Research and Clinical Practice 2007; 76:390-396	95
Chapter 8	No effect of statin therapy on silent myocardial ischemia in patients with type 2 diabetes without manifest cardiovascular disease Diabetes Care 2005; 28: 1675-1679	107
Chapter 9	Summary and Conclusions	119
Chapter 10	Samenvatting	127
	Curriculum Vitae	135
	Publicaties	137

ABBREVIATIONS

AECG	Ambulatory Electrocardiogram
AI	Asian Indian
AIX	Augmentation Index
ALT	Alanine Aminotransferase
BMI	Body Mass Index
CAC	Coronary Artery Calcium
CAD	Coronary Artery Disease
CCA	Common Carotid Artery
CE	Coronary Events
CIMT	Carotid Intima-media Thickness
CRP	C-Reactive Protein
CTAD	citrate, theophylline, adenosine, dipyridamol
CVD	Cardiovascular Disease
DM2	type 2 Diabetes Mellitus
EC	Europid Caucasian
EIA	Enzyme Immuno Assay
FMD	Flow Mediated Dilation
HDL	High density lipoprotein
LDL	Low density lipoprotein
IMT	Intima-media Thickness
MPI	Myocardial Perfusion Imaging
MS	Metabolic Syndrome
MSCT	Multi-Slice Computed Tomography
NMD	Nitroglycerin Mediated Dilation
NO	Nitric Oxide
PAI-1	Plasminogen Activator Inhibitor-1
PWV	Pulse Wave Velocity
QTc	QT interval corrected for heart rate
SE	Stress Echocardiography
SMI	Silent Myocardial Ischemia
SPECT	single photon emission computed tomography
Statins	HydroxyMethylGlutaryl coenzyme A reductase inhibitors
sTM	s-Thrombomodulin
tPA	tissue type Plasminogen Activator
VLDL	Very low density lipoprotein
VWF	von Willebrand Factor

